Apheresis Market

Apheresis Market Overview

The Apheresis Market is expected to grow at 13 % CAGR from 2024 to 2033. It is expected to reach above USD 13.26 billion by 2033 from USD 4.26 billion in 2024.

Blood is extracted from a donor, one or more blood components, such as platelets, white blood cells, or plasma, are extracted, and the remaining blood is then transfused back into the donor at any stage of the process. This process is known as apheresis. During apheresis, whole blood from a donor or patient is transformed within a machine that functions essentially as a centrifuge, separating the components of whole blood. One of the divided pieces is then removed, and the remaining portions are re-transfused back into the donor.

Increases in the number of injury cases, the prevalence of chronic diseases, the demand for source plasma from biopharmaceutical companies, the demand for blood components and the growing concerns about blood safety, the number of complex surgical procedures, and the favorable reimbursement for apheresis procedures are the main factors driving the apheresis market. The high expense of apheresis devices, therapeutic apheresis procedures, and rental-model apheresis device installation, along with a decline in apheresis-assisted blood donations brought on by ignorance and stringent donor recruitment requirements, are expected to limit market expansion in the years to come.

The primary drivers of the apheresis industry's expansion are the rise in government initiatives to encourage blood donation and the increased demand for blood components worldwide. Furthermore, market expansion is supported by newly approved apheresis treatment indications for acute disseminated encephalomyelitis, cardiac neonatal lupus, and autoimmune hemolytic anemia. The FDA (Food and Drug Administration) authorized NexSys PCS with persona technology in October 2020. This technology customizes plasma collection according to a donor's distinct body composition. It is produced by the blood management product company Haemoneticsis. Issues facing the apheresis industry include a lack of skilled professionals and a shift in technology that makes it more expensive to hire trained staff. Because childhood illnesses like leukemia and autoimmune disorders are so common, using therapeutic apheresis in pediatric therapy might help the market grow, but it is a challenging technological undertaking. More work is required to create fresh approaches to apheresis treatment tailored to children.

Apheresis Market Segment Analysis

The market for apheresis is divided into segments according to end users, components, methods, procedures, and products. The category with the most market share in 2021 was disposable & reagents, depending on the product. Due to the notable advancements in the production of disposable kits, tubing, and blood bags, this trend is expected to continue throughout the projected period. However, it is projected that the same category will grow significantly during the course of the apheresis market estimate. The centrifugation segment dominated the market size for apheresis as a method in 2021, and this trend is expected to continue during the forecast period due to the widespread use of centrifugation in the preparation of blood components like packed red blood cells (PRBCs) and fresh frozen plasma (FFP) in a single-step heavy spin.

Blood centers control the majority of the apheresis industry, with the donor/automated sector dominating by procedure in 2021. Increased contributions from platelets and plasma have led to the growth of the sector. Due to its extensive usage in the treatment of hematologic, neurological, renal, and metabolic disorders, plasma apheresis is the most popular method. Because of its growing popularity, platelet apheresis is predicted to rise. The end-user market is dominated by blood centers.

Apheresis Market Players

• Asahi Kasei Corporation
• Braun SE
• Fresenius SE & Co. KGAA (Fresenius Kabi AG)
• Haemonetics Corporation
• Terumo Corporation (Terumo BCT Inc.)
• Kaneka Corporation
• Sumitomo Bakelite Company Limited (Kawasumi Laboratories Inc.)
• Medica SPA
• Baxter International
• Cerus Corporation
• Macopharma SA
• Otsuka Holdings Co. Ltd (JIMRO Co., Ltd)

Recent Developments:

19 April 2023: On April 19, 2023, Asahi Kasei Medical announced the completion of its acquisition of Bionova Scientific, LLC, a company that offers biopharmaceutical businesses contract manufacturing services that comply with GMP and contract process development services. On May 31, 2023 (US Pacific time), the purchase was finalized.

ExThera Medical and Asahi Kasei Medical, a key business of the Asahi Kasei Group, have signed an exclusive distribution contract for ExThera's Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) in Japan as of December 21, 2021. ExThera Medical and Asahi Kasei Medical will work together to get regulatory clearance for Seraph 100's commercialization in Japan in accordance with the terms of the agreement.

Apheresis Market Regional Analysis

The rising prevalence of blood disorders, well-established healthcare systems, and high patient awareness are all factors contributing to the anticipated growth of the North American blood market. In the United States, 9.8% of all new cancer cases in 2021 will be blood cancer. The UnitedHealthcare Commercial Medica Policy and other growing reimbursement policies for apheresis treatments and equipment are fueling demand among the target demographic and propelling the nation's apheresis market. In order to honor donors, patients, and professionals for their efforts to promote apheresis medicine and raise awareness, the American Society for Apheresis (ASFA) has designated September 21, 2021, as Apheresis Awareness Day. This is anticipated to increase the apheresis industry in North America.

Apheresis Market Trends

Hematologic disorders, including red blood cells, white blood cells, platelets, bone marrow, lymph nodes, and spleen, significantly impact global morbidity and mortality. Sickle cell disease affects around 100,000 Americans and 1 out of every 365 Black or African American births. Early diagnosis and treatment are crucial for patients with blood cell disorders. Apheresis, a treatment method for hematological disorders, is expected to grow due to increasing incidences and growing applications. Therapeutic apheresis, such as immunoadsorption, double filtration, and cytapheresis, are used in treating autoimmune renal diseases and managing sickle cell anemia.

Key Market Segments: Apheresis Market

Apheresis Market By Product, 2024-2033, (USD Billion)

• Devices
• Disposable & Reagents
• Software

Apheresis Market By Method, 2024-2033, (USD Billion)

• Centrifugation
• Membrane Separation
• Selective Absorption

Apheresis Market By Procedure, 2024-2033, (USD Billion)

• Donor/Automated Apheresis
• Therapeutic Apheresis

Apheresis Market By Component, 2024-2033, (USD Billion)

• Plasma
• Platelets
• Leukocytes
• Lymphocytes
• RBCs

Apheresis Market By End User, 2024-2033, (USD Billion)

• Blood Centers
• Hospitals
• Others

Apheresis Market By Region, 2024-2033, (USD Billion)

• North America
• Asia Pacific
• Europe
• South America
• Middle East And Africa

Apheresis Market Report Scope